Skip to main content
TIANYU BIO-TECHNOLOGY CO.,LTD. logo

TIANYU BIO-TECHNOLOGY CO.,LTD. — Investor Relations & Filings

Ticker · 603717 ISIN · CNE1000030W1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,621 across all filing types
Latest filing 2025-06-27 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603717

About TIANYU BIO-TECHNOLOGY CO.,LTD.

https://www.tianyubiotech.com/

TIANYU BIO-TECHNOLOGY CO.,LTD. specializes in the research, development, and large-scale production of active pharmaceutical ingredients (APIs) and advanced pharmaceutical intermediates. The company focuses on therapeutic areas such as cardiovascular health, diabetes management, and anti-viral treatments. Its core product portfolio includes various sartan-based intermediates and other complex organic synthesis products. TIANYU BIO-TECHNOLOGY emphasizes rigorous quality management systems and adheres to international regulatory standards to ensure product safety and efficacy. By leveraging advanced chemical synthesis technologies and a robust R&D infrastructure, the company provides customized manufacturing solutions and high-quality chemical components to global pharmaceutical partners. Its operations are characterized by a commitment to technical innovation and process optimization in the synthesis of complex molecules.

Recent filings

Filing Released Lang Actions
关于公司2025年度对外担保预计的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's external guarantees for the year 2025, detailing the guarantee amounts, the parties involved, internal decision procedures, and financial data of the guaranteed party. It includes specifics about guarantee contracts and board approvals. The document is relatively short (2715 characters) and focuses on a specific financial guarantee update rather than a full financial report or audit. It does not contain comprehensive financial statements or detailed financial performance analysis. It is a regulatory announcement about financing-related guarantees, which fits best under Capital/Financing Update (CAP).
2025-06-27 Chinese
关于公司2025年度对外担保预计的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Tianyu Bio-Technology Co., Ltd. regarding the progress of external guarantees for the year 2025. It includes specifics about guarantee amounts, the companies involved, financial data of subsidiaries, internal decision procedures, and board opinions. The content focuses on the company's external guarantee commitments and related financial risks, which is typical of a capital/financing update. There is no indication that this is a full annual or interim report, audit report, or earnings release. The document is longer than 5,000 characters and contains substantive financial and operational details about guarantees, not just an announcement of a report. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2025-06-23 Chinese
关于提前归还部分暂时用于补充流动资金的闲置募集资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about the early repayment of part of idle raised funds temporarily used to supplement working capital. It discusses the board's approval, specific amounts repaid, and references previous announcements. The content focuses on capital management and financing activities rather than financial results or reports. The document length is short (719 characters), and it is a formal announcement about capital usage and repayment, fitting the Capital/Financing Update category rather than a full financial report or regulatory filing.
2025-06-19 Chinese
关于收到《裁决书》暨业绩补偿事项的仲裁进展公告
Legal Proceedings Report Classification · 95% confidence The document is an announcement from a company regarding the receipt of an arbitration award (裁决书) related to a performance compensation dispute. It details the arbitration stage, the parties involved, the amount in dispute, and the potential impact on the company's profits. The document does not contain financial statements or detailed financial data but rather provides an update on legal proceedings and their potential financial impact. This fits the definition of a Legal Proceedings Report (LTR), which covers updates on significant lawsuits, regulatory actions, or legal matters involving the company.
2025-06-16 Chinese
2025年5月养殖业务主要经营数据公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (1052 characters) from Tianyu Bio-Technology Co., Ltd. presenting the main operating data for its breeding business for May 2025. It includes monthly sales volume, sales revenue, and inventory data, with comparisons to previous months and year-on-year changes. The document explicitly states that the data is unaudited and for investor reference only, indicating it is a periodic operational update rather than a full financial report. There is no indication of comprehensive financial statements or detailed analysis typical of interim or annual reports. The document is not a full quarterly or interim report but a monthly business data announcement. Given the short length and nature of the content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-06-06 Chinese
2025年4月养殖业务主要经营数据公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (1002 characters) providing monthly operational data for April 2025 related to the company's pig farming business. It includes sales volume, sales revenue, and inventory data, with comparisons to previous months and year-on-year changes. The document explicitly states that the data is unaudited and may differ from periodic reports, serving as interim operational data for investor reference. There are no comprehensive financial statements or detailed analysis typical of interim or annual reports. The document is not a full financial report but a business update announcement. Given the short length and nature of the content, it fits best as a Regulatory Filing (RNS) rather than an Interim Report (IR) or Earnings Release (ER).
2025-05-09 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.